Xizang Weixinkang Pharmaceutical Co., Ltd.

Weixinkang Pharmaceutical was established in 2002, officially founded in 2006, formally renamed Xizang Weixinkang Pharmaceutical Co.,Ltd. in 2013, Xizang Weixinkang Pharmaceutical Co.,Ltd. listed on the mainboard of the Shanghai Stock Exchange (stock code 603676.SH) in 2017, with 13 subsidiaries and nearly 800 employees, distributed in Beijing, Xizang, Inner Mongolia, Hainan, Jiangsu, Hong Kong Singapore and other places. 

Guided by clinical needs, the company focuses on the R&D and innovation of generic and innovative drugs. Weixinkang is a comprehensive high-tech medical enterprise integrating medicine R&D, production, and sales, with significant advantages in intravenous vitamins, intravenous trace elements, and intravenous electrolytes，etc. 

Weixinkang is a specialist in parenteral nutrition for adults and children. The major products of the company include Multivitamin For Injection (12), Multivitamins For Injection (13)(10/3)，Pediatric Multivitamins For Injection (13), Concentrate Of Trace Elements Solution for Infusion, Compound Amino Acid Injection (20AA), Pediatric Compound Amino Acid Injection (19AA-I), Acetylcysteine Solution For Inhalation, Potassium Aspartate and Magnesium Aspartate Injection, Iron Sucrose Injection, Multiple Electrolytes Injection (II), Multiple Electrolytes Injection (V), and Carbohydrate Electrolyte Injection. 

Weixinkang’s R&D Center has nearly 200 researchers, including lead researchers with an average of over 10 years of experience in drug R&D. Currently, the company has established three technological platforms for R&D, namely the “new injection process platform”, “large compound formulation platform”, and “new lyophilization platform and is extending to cover oral solid formation and new drug delivery system. The company has obtained 14 invention patents during its independent R&D. Since 2015, Weixinkang has obtained 17 new drug certificates and 19 registration approvals for 13 drug products. In addition, the company has over 40 R&D projects and many projects under registration review and approval. Weixinkang has established a professional and efficient market sales network, with a business system covering over 3,000 second-tier and above medical institutions and mainstream commercial channels across the country and most provinces, providing professional and customized commercial solutions for partners.

The “people-oriented and excellence-driven” talent philosophy of Weixinkang has attracted many professionals and laid a solid talent foundation for the company’s long-term development. With firm roots in China and visions for global expansion, Weixinkang will continue to adhere to the mission of “good health and well-being” by focusing on health services and new research frontiers, following the development trend of the pharmaceutical industry, and continuously strengthening innovative and technological capacities in order to provide more innovative and accessible treatment options for patients worldwide. Weixinkang strives to become a leading generic and innovative drug manufacturer in the modernized, scaled up high-tech pharmaceutical industry.